“Regorafenib Therapy Promising in Metastatic Colorectal Cancer: Higher Doses, Right-Sided Colon Cancer, and KRAS Mutations Associated with Longer Survival Despite Adverse Events”

https://pubmed.ncbi.nlm.nih.gov/38115370

Regorafenib therapy as a third-line treatment in metastatic colorectal cancer shows promising progression-free and overall survival rates, with longer durations in patients starting at higher doses, those with right-sided colon cancer, and those with KRAS mutations, despite common adverse events such as elevated liver enzymes and dermatological toxicities.